- Home
- RLAY vs ESNT Comparison
RLAY vs ESNT Comparison
Compare RLAY & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- ESNT
- Stock Information
- Founded
- RLAY 2015
- ESNT 2008
- Country
- RLAY United States
- ESNT Bermuda
- Employees
- RLAY N/A
- ESNT N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- ESNT Property-Casualty Insurers
- Sector
- RLAY Health Care
- ESNT Finance
- Exchange
- RLAY Nasdaq
- ESNT Nasdaq
- Market Cap
- RLAY 803.4M
- ESNT N/A
- IPO Year
- RLAY 2020
- ESNT 2013
- Fundamental
- Price
- RLAY $7.52
- ESNT $59.89
- Analyst Decision
- RLAY Strong Buy
- ESNT Buy
- Analyst Count
- RLAY 8
- ESNT 6
- Target Price
- RLAY $17.25
- ESNT $65.67
- AVG Volume (30 Days)
- RLAY 1.9M
- ESNT 660.0K
- Earning Date
- RLAY 11-07-2025
- ESNT 11-07-2025
- Dividend Yield
- RLAY N/A
- ESNT 2.05%
- EPS Growth
- RLAY N/A
- ESNT N/A
- EPS
- RLAY N/A
- ESNT 6.85
- Revenue
- RLAY $8,355,000.00
- ESNT $1,268,306,000.00
- Revenue This Year
- RLAY $27.30
- ESNT $4.27
- Revenue Next Year
- RLAY $7.43
- ESNT $1.54
- P/E Ratio
- RLAY N/A
- ESNT $8.74
- Revenue Growth
- RLAY N/A
- ESNT 5.28
- 52 Week Low
- RLAY $1.78
- ESNT $51.61
- 52 Week High
- RLAY $7.60
- ESNT $65.90
- Technical
- Relative Strength Index (RSI)
- RLAY 71.60
- ESNT 43.16
- Support Level
- RLAY $6.30
- ESNT $58.46
- Resistance Level
- RLAY $7.50
- ESNT $61.74
- Average True Range (ATR)
- RLAY 0.52
- ESNT 1.03
- MACD
- RLAY 0.03
- ESNT 0.06
- Stochastic Oscillator
- RLAY 95.54
- ESNT 43.60
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).